Scotty Sengsavang

Scotty Sengsavang is an experienced leader in program management and drug development within the pharmaceutical industry. Currently serving as the Head of Program Leadership at Inhibikase Therapeutics, Inc., Scotty oversees the development of key drugs for Parkinson's Disease and Pulmonary Arterial Hypertension while establishing operational models and program management processes. Previous roles include Senior Director of Program Management at Finch Therapeutics, where Scotty led research and development for treatments of Ulcerative colitis and Crohn's disease, and Global Program Executive at Praxis Precision Medicines, focusing on psychiatric therapies. Additional experience at Takeda and Viridian Therapeutics involved leading cross-functional teams in strategy and product lifecycle management for rare diseases and oncology products. Scotty holds an MBA from Webster University and a Master of Science from Middle Tennessee State University.